Artradol

Indications

Degenerative-dystrophic diseases of the joints and spine: primary osteoarthritis, osteoarthritis predominantly affecting large joints, intervertebral osteochondrosis.
To accelerate the formation of callus in fractures.

Section: Method of Application and Dosage

In degenerative-dystrophic diseases of the joints and spine, a starting dose of chondroitin sulfate is administered intramuscularly at 100 mg every other day (the use of the drug ARTRADOL® lyophilisate for the preparation of a solution for intramuscular injection, 100 mg, is possible; before use, the contents of the ampoule are dissolved in 1 ml of injection water). Then, starting from the fourth injection, with good tolerance, the dose is increased to 200 mg intramuscularly every other day. Before use, the contents of the ampoule are dissolved in 2 ml of injection water. The treatment course consists of 25-35 injections. If necessary, a repeat treatment course may be conducted after 6 months. The duration of repeat treatment courses is determined by the doctor.
For the formation of a bone callus, the treatment course lasts 3-4 weeks (10-14 injections every other day).

Section: Composition

One ampoule contains:
Active ingredient:
Sodium chondroitin sulfate - 200 mg (calculated as 100% substance)

Description of the dosage form

White or white with a yellowish tint amorphous porous mass, whole or crushed, or compressed in the form of a tablet.

• hypersensitivity;

• pregnancy and breastfeeding;

• children and adolescents under 18 years old (efficacy and safety not established).
With caution
Bleeding and tendency to bleed, thrombophlebitis. Pregnancy, breastfeeding (safety data is lacking).
Use during pregnancy and breastfeeding
The drug is contraindicated for use during pregnancy and breastfeeding (breastfeeding should be discontinued during treatment).

Special instructions

When the drug is used in conjunction with indirect anticoagulants, antiplatelet agents, and fibrinolytics, more frequent monitoring of blood coagulation parameters is required.
Effect on the ability to drive vehicles and operate machinery
The drug does not affect the ability to drive vehicles, operate machinery, or engage in other activities that require increased attention and quick psychomotor reactions.

Side effects

Disorders of the immune system: allergic reactions (skin itching, erythema, urticaria, dermatitis, swelling).
General disorders and reactions at the injection site: hemorrhages at the injection sites.

Overdose

Information on overdose is not available.

Interaction

Possible enhancement of the action of indirect anticoagulants, antiplatelet agents, fibrinolytics.

Pharmacodynamics

Chondroitin sulfate is the main component of proteoglycans, which together with collagen fibers form the cartilage matrix. It has chondroprotective properties; it inhibits the activity of enzymes that cause the degradation of articular cartilage; it stimulates the production of proteoglycans by chondrocytes; it enhances metabolic processes in cartilage and subchondral bone; it influences phosphorus-calcium metabolism in cartilage tissue, stimulates its regeneration, and participates in the construction of the fundamental substance of bone and cartilage tissue.
It has anti-inflammatory and analgesic properties, contributes to the reduction of the release of inflammatory mediators and pain factors into the synovial fluid through synoviocytes and macrophages of the synovial membrane, and inhibits the secretion of leukotriene B4 and prostaglandin E2.
The drug promotes the restoration of cartilage surfaces of joints, prevents the collapse of connective tissue; it normalizes the production of synovial fluid, which leads to improved joint mobility and reduced pain intensity.
Having structural similarity to heparin, it may potentially prevent the formation of fibrin clots in the synovial and subchondral microcirculatory pathways.

Pharmacokinetics

Absorption
After intramuscular administration, the maximum concentration of the drug in the blood plasma (Cmax) is reached 1 hour after administration; then the concentration of the drug gradually decreases over 2 days.
Distribution
After intramuscular administration, chondroitin sulfate is rapidly distributed. Already 30 minutes after the injection, it is found in the blood in significant concentrations. Chondroitin sulfate accumulates mainly in the cartilage tissue of the joints. The synovial membrane does not pose a barrier to the penetration of the drug into the joint cavity. Experiments have shown that 15 minutes after intramuscular injection, chondroitin sulfate is found in the synovial fluid, then it penetrates into the articular cartilage, where its Cmax is reached after 48 hours.
Metabolism and elimination
It is excreted from the body mainly by the kidneys within 24 hours.